
Reset all filters
01 7Fiasp
02 6NovoMix
03 1NovoMix/NovoLog Mix
04 6NovoRapid
05 1NovoRapid/NovoLog
06 2Novomix/Novolog Mix
07 2Novorapid/Novolog
08 11Ryzodeg
09 8Tresiba
10 5Xultophy
Insulin Degludec, Insulin Aspart
Main Therapeutic Indication : Diabetes
Currency : USD
2020 Revenue in Millions : 210
2019 Revenue in Millions : 162
Growth (%) : 30
Main Therapeutic Indication : Diabetes
Currency : USD
2020 Revenue in Millions : 1,567
2019 Revenue in Millions : 1,559
Growth (%) : 1
Main Therapeutic Indication : Diabetes
Currency : USD
2020 Revenue in Millions : 2,753
2019 Revenue in Millions : 2,937
Growth (%) : -6
Insulin Degludec, Insulin Aspart
Main Therapeutic Indication : Diabetes
Currency : USD
2020 Revenue in Millions : 398
2019 Revenue in Millions : 359
Growth (%) : 11
Main Therapeutic Indication : Diabetes
Currency : USD
2020 Revenue in Millions : 210
2019 Revenue in Millions : 162
Growth (%) : 30
Main Therapeutic Indication : Diabetes
Currency : USD
2020 Revenue in Millions : 225
2019 Revenue in Millions : 202
Growth (%) : 11
Insulin Degludec, Insulin Aspart
Main Therapeutic Indication : Diabetes
Currency : USD
2020 Revenue in Millions : 1,459
2019 Revenue in Millions : 1,506
Growth (%) : -3
Main Therapeutic Indication : Diabetes
Currency : USD
2021 Revenue in Millions : 266
2020 Revenue in Millions : 222
Growth (%) : 26
Insulin Degludec, Insulin Aspart
Main Therapeutic Indication : Diabetes
Currency : USD
2021 Revenue in Millions : 405
2020 Revenue in Millions : 391
Growth (%) : 9
Main Therapeutic Indication : Diabetes
Currency : USD
2021 Revenue in Millions : 1,447
2020 Revenue in Millions : 1,541
Growth (%) : -1